Lab21 – A New Kind of Company
Antiviral drug discovery services and clinical trials support
Cambridge, UK & Fareham, UK – July 15, 2005 – A new company – Lab21 – has been launched to provide technically advanced drug discovery and clinical trials services to the pharmaceutical and biotech industries. Testing is performed in state-of-the-art laboratories in Cambridge (UK), with commercial headquarters in Fareham (UK). Lab21 brings together high level drug discovery experience, expert know-how and an unmatched range of superior testing technologies – all delivered with the demands of the regulatory bodies in mind.
An extensive array of spearhead tests and services are available including lead identification and optimisation, resistance profiling, clinical candidate selection and selectivity evaluation in pre-clinical situations. And once a drug is in the clinic, Lab21 offers pharmacogenetic testing and trial stratification, FDA requirements for registration, efficacy studies and resistance monitoring.
Lab21 is the only company of its kind in the UK. Supported financially by Merlin Biosciences, Merlin's Chairman, Professor Sir Christopher Evans OBE leads the Lab21 board of directors.
Many industry leaders foresee a more effective and efficient future for healthcare delivery. A time when pharmacogenetic profiling will allow prediction of the risk of certain diseases or conditions developing, and we reach a full understanding of the impact an individual's genetic make-up, lifestyle choices and environmental factors can have on disease progression and response to therapy.
Dr Nick Kerton, CEO of Lab21 commented:
"We believe that Lab21 has already made significant progress towards the goal of personalised healthcare. Our customers can benefit today from a unique portfolio of tests that allow the characterisation of a virus, the assessment of prospective drug candidates, and the understanding of potential resistance. In addition, we can genotype a trials population, assess their pharmacogenetics, or monitor patients undergoing therapy."
For full details of Lab21, its tests and services visit www.lab-21.com
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Phase III SELECT-GCA Trial Results Lead to FDA Approval of Rinvoq for Giant Cell Arteritis
April 30th 2025Rinvoq (upadacitinib) becomes the first oral JAK inhibitor approved by the FDA for the treatment of giant cell arteritis in adults, following robust data from the Phase III SELECT-GCA trial demonstrating its efficacy in achieving sustained remission and reducing glucocorticoid exposure.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
